Related Experiment Videos
Quantitative counterimmunoelectrophoresis assay for prostatic acid phosphatase
Investigative Urology
|November 1, 1980
Summary
New quantitative assays for prostatic acid phosphatase (PAP) detect elevated levels in early prostate cancer. These sensitive methods improve detection beyond conventional chemical tests.
Area of Science:
- Immunology
- Clinical Chemistry
- Oncology
Background:
- Prostatic acid phosphatase (PAP) is a biomarker for prostate health.
- Conventional methods may lack sensitivity for detecting early-stage prostate cancer.
- Quantitative detection of PAP is crucial for accurate diagnosis.
Purpose of the Study:
- To develop and validate novel quantitative assays for serum PAP detection.
- To enhance the sensitivity and reliability of PAP measurement.
- To assess the utility of these assays in identifying early prostate cancer.
Main Methods:
- Development of two quantitative counterimmunoelectrophoretic assays: CIE-C (colorimetric) and CIE-D (densitometric).
- Utilization of a primary standard for accurate PAP quantitation.
- Validation through precision, coefficient of variation, and recovery studies over 3 months.
Main Results:
- Achieved high sensitivity: 0.08 IU/L for CIE-C and 0.04 IU/L for CIE-D.
- Demonstrated assay reliability and reproducibility.
- Identified elevated PAP levels in patients with early prostate cancer, missed by conventional methods.
Conclusions:
- The developed CIE-C and CIE-D assays offer sensitive and reliable quantitative detection of serum PAP.
- These assays can detect elevated PAP in early prostate cancer stages, outperforming conventional chemical methods.
- The improved detection capabilities hold significant potential for earlier and more accurate prostate cancer diagnosis.